here is an ongoing debate about the role of coronary revascularization in the setting of non-ST-segment elevation myocardial infarction (NSTEMI). American and European guidelines currently agree that an early invasive strategy is recommended in patients with at least 1 high-risk criterion (1,2). However, the optimal treatment strategy for patients with multivessel disease is still unclear. Multivessel disease occurs frequently: it is encountered in approximately 50% of patients with NSTEMI undergoing coronary angiography (3,4). in the multistage group was unprecedentedly high in the era of current-generation drug-eluting stents. The only study that comes close to this high event rate is the SYNTAX (Synergy between PCI with TAXUS and Cardiac Surgery) trial, where the 1-year repeat revascularization rate (including TVR, but also non-TVR) was 13.5% in the PCI arm (6). However, in SYNTAX, the mean SYNTAX score was 28, compared with 15 in the current study, and obsolete first-generation paclitaxel-eluting stents were used (7).
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